期刊
GASTROENTEROLOGY CLINICS OF NORTH AMERICA
卷 46, 期 3, 页码 577-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.gtc.2017.05.009
关键词
Crohn's disease; Inflammatory bowel diseases; Immunology; Target therapy
Understanding the immunologic pathways in intestinal inflammation is crucial for the development of new therapies that can maximize patient response and minimize toxicity. Targeting integrins and cytokines is intended to control leukocyte migration to effector sites or inhibit the action of proinflammatory cytokines. New approaches to preventing leukocyte migration may target integrin receptors expressed on the intestinal vascular endothelium. The interleukin (IL)-12/1L-23 pathway has been a therapeutic target of interest in controlling active Crohn's disease (CD). New therapeutic approaches in CD may involve the enhancement of anti-inflammatory cytokine pathways and modulation of cellular responses and intranuclear signals associated with intestinal inflammation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据